Topamax
Epilepsy, Absence
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Epilepsy, Absence cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brivaracetam Film-Coated UCB Biopharma SRL | Phase 3 | BB |
Brivaracetam UCB Biopharma SRL | Phase 3 | BB |
Ethosuximide Children's Hospital Medical Center, Cincinnati | Phase 3 | BB |
LAMOTRIGINE Children's Hospital Medical Center, Cincinnati | Phase 3 | BB |
Valproic Acid Children's Hospital Medical Center, Cincinnati | Phase 3 | B |
Npt 2042 NeuroPro Therapeutics, Inc. | Phase 2 | CCC |
FLUNARIZINE HCL University of British Columbia | Phase 2 | CCC |
Bmb-101 Bright Minds Biosciences Pty Ltd | Phase 2 | NR |
Same molecule, other indications
Topamax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →